Diabetic retinopathy - ocular complications of diabetes mellitus.

In industrialized nations diabetic retinopathy is the most frequent microvascular complication of diabetes mellitus and the most common cause of blindness in the working-age population. In the next 15 years, the number of patients suffering from diabetes mellitus is expected to increase significantly. By the year 2030, about 440 million people in the age-group 20-79 years are estimated to be suffering from diabetes mellitus worldwide (prevalence 7.7%), while in 2010 there were 285 million people with diabetes mellitus (prevalence 6.4%). This accounts for an increase in patients with diabetes in industrialized nations by 20% and in developing countries by 69% until the year 2030. Due to the expected rise in diabetic patients, the need for ophthalmic care of patients (i.e., exams and treatments) will also increase and represents a challenge for eye-care providers. Development of optimized screening programs, which respect available resources of the ophthalmic infrastructure, will become even more important. Main reasons for loss of vision in patients with diabetes mellitus are diabetic macular edema and proliferative diabetic retinopathy. Incidence or progression of these potentially blinding complications can be greatly reduced by adequate control of blood glucose and blood pressure levels. Additionally, regular ophthalmic exams are mandatory for detecting ocular complications and initiating treatments such as laser photocoagulation in case of clinical significant diabetic macular edema or early proliferative diabetic retinopathy. In this way, the risk of blindness can considerably be reduced. In advanced stages of diabetic retinopathy, pars-plana vitrectomy is performed to treat vitreous hemorrhage and tractional retinal detachment. In recent years, the advent of intravitreal medication has improved therapeutic options for patients with advanced diabetic macular edema.

[1]  M. Ulbig,et al.  The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy. , 2012, Deutsches Arzteblatt international.

[2]  R. Klein,et al.  Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.

[3]  J. Olson,et al.  Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme , 2013, Diabetologia.

[4]  M. Postorino,et al.  Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema , 2013, Ophthalmologica.

[5]  A. Kampik,et al.  ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Decreasing Incidence and Clinical Outcome—8-year Results from a Tertiary Ophthalmic Referral Center , 2014, Retina.

[6]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[7]  F. Fajnkuchen,et al.  ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Anti-VEGF Therapy For Diabetic Macular Edema , 2015 .

[8]  Risk stratification for diabetic eye screening , 2013, Diabetologia.

[9]  H. Ahsan Diabetic retinopathy--biomolecules and multiple pathophysiology. , 2015, Diabetes & metabolic syndrome.

[10]  W. Rathmann,et al.  Epidemiologie und Verlauf des Diabetes mellitus in Deutschland , 2004 .

[11]  Lloyd Paul Aiello,et al.  Nonmydriatic ultrawide field retinal imaging compared with dilated standard 7-field 35-mm photography and retinal specialist examination for evaluation of diabetic retinopathy. , 2012, American journal of ophthalmology.

[12]  Laurel Beckett,et al.  Reproducibility of macular thickness measurement among five OCT instruments: effects of image resolution, image registration, and eye tracking. , 2012, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[13]  Nationale Versorgungsleitlinie Typ-2-Diabetes – Prävention und Therapie von Netzhautkomplikationen , 2006 .

[14]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[15]  Marco A Zarbin,et al.  Diabetic macular edema: pathogenesis and treatment. , 2009, Survey of ophthalmology.

[16]  K. Lemmen Medikamentöse Therapie der diabetischen Retinopathie und Makulopathie , 2008, Der Diabetologe.

[17]  A. Kampik,et al.  Assessment of Diabetic Retinopathy Using Nonmydriatic Ultra-Widefield Scanning Laser Ophthalmoscopy (Optomap) Compared With ETDRS 7-Field Stereo Photography , 2012, Diabetes Care.

[18]  C. Bührer,et al.  Diabetes und Schwangerschaft , 2008 .

[19]  A. Sjølie,et al.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes , 1998, The Lancet.

[20]  G. Roglić,et al.  Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[21]  A. Sjølie,et al.  Is Smoking a Risk Factor for Proliferative Diabetic Retinopathy in Type 1 Diabetes? , 2013, Ophthalmologica.

[22]  H. Flynn,et al.  ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS: Office-Based Setting and Operating Room Setting , 2014, Retina.

[23]  A. Harris,et al.  Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant , 2014, Expert opinion on pharmacotherapy.

[24]  T Bek,et al.  Screening and prevention of diabetic blindness. , 2000, Acta ophthalmologica Scandinavica.

[25]  P. Keane,et al.  RISK FACTORS FOR PROLIFERATIVE DIABETIC RETINOPATHY IN A LATINO AMERICAN POPULATION , 2012, Retina.

[26]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[27]  B. Rhee,et al.  Prevalence and factors associated with diabetic retinopathy in a Korean adult population: the 2008-2009 Korea National Health and Nutrition Examination Survey. , 2013, Diabetes research and clinical practice.

[28]  E. Stefánsson,et al.  Biennial eye screening in patients with diabetes without retinopathy: 10-year experience , 2007, British Journal of Ophthalmology.

[29]  G. Yancopoulos,et al.  VEGF-initiated blood-retinal barrier breakdown in early diabetes. , 2001, Investigative ophthalmology & visual science.

[30]  M. Maia,et al.  Anti-VEGF for the Management of Diabetic Macular Edema , 2014, Journal of immunology research.

[31]  T. Gardner,et al.  Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment , 2014, Annals of the New York Academy of Sciences.

[32]  H. Novotny,et al.  A Method of Photographing Fluorescence in Circulating Blood in the Human Retina , 1961, Circulation.

[33]  M. Grueterich,et al.  Application of 10% Povidone Iodine Reduces Conjunctival Bacterial Contamination Rate in Patients Undergoing Cataract Surgery , 2012, European journal of ophthalmology.

[34]  J. Kerrison,et al.  Metabolic control and diabetic retinopathy. , 2009, Current diabetes reviews.

[35]  R. Schlingemann,et al.  Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions , 2013, Progress in Retinal and Eye Research.

[36]  R. Retnakaran,et al.  Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[37]  J. Gross,et al.  Diabetic Retinopathy Predicts All-Cause Mortality and Cardiovascular Events in Both Type 1 and 2 Diabetes , 2011, Diabetes Care.

[38]  Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.

[39]  Thomas W. Gardner,et al.  The restore study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema , 2011 .

[40]  J. C. Gines,et al.  Bakterielle Kontamination von Injektionskanülen nach intravitrealer operativer Medikamenteneingabe in Paraguay , 2012, Der Ophthalmologe.

[41]  Szilárd Kiss,et al.  ULTRA–WIDE-FIELD ANGIOGRAPHY IMPROVES THE DETECTION AND CLASSIFICATION OF DIABETIC RETINOPATHY , 2012, Retina.

[42]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[43]  A. Sjølie,et al.  Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients , 2012, Acta Diabetologica.

[44]  H. Hammes Optimal treatment of diabetic retinopathy , 2013, Therapeutic advances in endocrinology and metabolism.

[45]  E. Stefánsson,et al.  Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy , 2011, Diabetologia.

[46]  T. Krohne,et al.  Diabetische Retinopathie , 2003, Der Ophthalmologe.

[47]  M. Nentwich,et al.  Diabetes und Auge , 2014, Der Diabetologe.

[48]  Elena Prokofyeva,et al.  Epidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review , 2011, Ophthalmic Research.

[49]  A. Kampik,et al.  Bacterial Contamination of Needle Points after Intravitreal Injection , 2009, European journal of ophthalmology.

[50]  B. Godley,et al.  Nicotine Accelerates Diabetes-Induced Retinal Changes , 2015, Current eye research.

[51]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[52]  T. Sørensen,et al.  NO CASES OF ENDOPHTHALMITIS AFTER 20,293 INTRAVITREAL INJECTIONS IN AN OPERATING ROOM SETTING , 2014, Retina.

[53]  S. Whitcup,et al.  Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. , 2014, Ophthalmology.

[54]  D. Park,et al.  COMPARISON OF CLINICAL OUTCOMES BETWEEN 23-GAUGE AND 20-GAUGE VITRECTOMY IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY , 2010, Retina.

[55]  Bing Li,et al.  Comparison of the efficacy of povidone–iodine 1.0%, 5.0%, and 10.0% irrigation combined with topical levofloxacin 0.3% as preoperative prophylaxis in cataract surgery , 2013, Journal of cataract and refractive surgery.

[56]  F. Verbraak Neuroretinal Degeneration in Relation to Vasculopathy in Diabetes , 2014, Diabetes.

[57]  Lala Ceklic,et al.  Nonmydriatic Ultra-Wide-Field Scanning Laser Ophthalmoscopy (Optomap) versus Two-Field Fundus Photography in Diabetic Retinopathy , 2013, Ophthalmologica.

[58]  E. Vaucher,et al.  The kallikrein-kinin system in diabetic retinopathy. , 2014, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[59]  H. Parving,et al.  Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.

[60]  P. Campochiaro,et al.  Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. , 2012, Ophthalmology.

[61]  A. Wenzel,et al.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance]. , 2010, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.